Published in Sleep on November 01, 2010
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med (2017) 1.17
Sleep neurobiology from a clinical perspective. Sleep (2011) 1.14
Psychiatric disorders and sleep. Neurol Clin (2012) 1.05
Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med (2014) 1.01
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep (2011) 0.99
Impact of brief cognitive behavioral treatment for insomnia on health care utilization and costs. J Clin Sleep Med (2014) 0.82
Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. Int J Mol Sci (2015) 0.82
Sensitivity and specificity of polysomnographic criteria for defining insomnia. J Clin Sleep Med (2013) 0.81
Effect of Placebo Conditions on Polysomnographic Parameters in Primary Insomnia: A Meta-Analysis. Sleep (2015) 0.78
The effects of doxepin on stress-induced learning, memory impairments, and TNF-α level in the rat hippocampus. Res Pharm Sci (2016) 0.77
Treatment of Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea During and After Menopause: Therapeutic Approaches. Curr Psychiatry Rev (2015) 0.77
Efficacy and safety of low-dose doxepin in depressed patients suffering from insomnia: a retrospective, naturalistic case series analysis. Prim Care Companion CNS Disord (2014) 0.76
Drug-induced sleep: theoretical and practical considerations. Pflugers Arch (2011) 0.76
Efficacy and safety evaluation of citalopram and doxepin on sleep quality in comorbid insomnia and anxiety disorders. Exp Ther Med (2015) 0.76
Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people. Can Pharm J (Ott) (2014) 0.76
Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard. Psychiatry Clin Neurosci (2001) 36.50
Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev (2002) 10.36
Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res (2004) 4.10
Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep (1999) 2.03
Epidemiological study on insomnia in the general population. Sleep (1996) 1.90
Insomnia in men-a 10-year prospective population based study. Sleep (2001) 1.81
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep (2007) 1.72
Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety (2003) 1.54
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry (2008) 1.51
Sleep complaints, subjective and objective sleep patterns, health, psychological adjustment, and daytime functioning in community-dwelling older adults. J Gerontol B Psychol Sci Soc Sci (2005) 1.49
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry (1994) 1.32
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry (2001) 1.19
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry (1999) 1.17
A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev (2009) 1.14
New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry (1992) 1.14
Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry (2000) 1.11
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep (2007) 1.07
Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol (1997) 1.01
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry (2008) 0.99
A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin (2006) 0.99
Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn't anyone care? Sleep Med Rev (2000) 0.92
The effects of doxepin HCl on sleep and depression. J Clin Psychiatry (1982) 0.91
Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr (2008) 0.91
A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med (2000) 0.91
Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol (1997) 0.89
'Young old' and 'old old' poor sleepers with and without insomnia complaints. J Psychosom Res (2003) 0.88
Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs (2007) 0.88
Treating insomnia in older adults: taking a long-term view. JAMA (1999) 0.86
Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging (1985) 0.81
History of the development of sleep medicine in the United States. J Clin Sleep Med (2005) 4.22
Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep (2004) 3.78
Epidemiology of insomnia, depression, and anxiety. Sleep (2005) 3.70
Sleep loss and REM sleep loss are hyperalgesic. Sleep (2006) 3.03
Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res (2002) 2.99
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry (2006) 2.86
The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res (2006) 2.60
Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med (2005) 2.51
Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res (2002) 2.48
Comorbidity of chronic insomnia with medical problems. Sleep (2007) 2.40
Early CPAP use identifies subsequent adherence to CPAP therapy. Sleep (2007) 2.19
Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study. Arch Gen Psychiatry (2004) 2.13
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry (2014) 2.10
Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics (2006) 2.06
The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med (2005) 1.87
The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep (2003) 1.86
Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep (2004) 1.84
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology (2012) 1.83
Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77
Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev (2001) 1.75
Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol (2009) 1.73
Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med (2010) 1.73
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep (2007) 1.72
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet (2008) 1.72
Insomnia as a health risk factor. Behav Sleep Med (2003) 1.72
Sleep and quality of life in breast cancer patients. J Pain Symptom Manage (2002) 1.65
The influence of age, gender, ethnicity, and insomnia on Epworth sleepiness scores: a normative US population. Sleep Med (2006) 1.63
Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety (2003) 1.54
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry (2008) 1.51
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol (2005) 1.48
Patient-reported outcomes in insomnia: development of a conceptual framework and endpoint model. Behav Sleep Med (2013) 1.43
Caffeine: sleep and daytime sleepiness. Sleep Med Rev (2007) 1.41
Socioeconomic status and insomnia. J Abnorm Psychol (2005) 1.41
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc (2009) 1.38
Sleep during titration predicts continuous positive airway pressure compliance. Sleep (2003) 1.37
Sleep and pain: interaction of two vital functions. Semin Neurol (2005) 1.37
Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep (2011) 1.35
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin (2004) 1.29
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin (2006) 1.28
Sleep hygiene practices in a population-based sample of insomniacs. Sleep (2005) 1.26
The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness. Sleep (2010) 1.25
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med (2011) 1.24
Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med (2007) 1.17
Ethanol and sleep loss: a "dose" comparison of impairing effects. Sleep (2003) 1.17
The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep (2006) 1.17
Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics (2006) 1.16
The relation between smoking and sleep: the influence of smoking level, health, and psychological variables. Behav Sleep Med (2004) 1.16
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Shift work sleep disorder: burden of illness and approaches to management. Drugs (2006) 1.15
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry (2008) 1.15
Zolpidem for insomnia. Expert Opin Pharmacother (2012) 1.14
A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med (2007) 1.14
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep (2008) 1.13
MSLT in primary insomnia: stability and relation to nocturnal sleep. Sleep (2011) 1.13
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry (2008) 1.12
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol (2006) 1.09
Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol (2002) 1.09
Reliability and validity of the brief insomnia questionnaire in the America insomnia survey. Sleep (2010) 1.08
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep (2007) 1.07
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry (2012) 1.07
Consequences of shiftworking on sleep duration, sleepiness, and sleep attacks. Chronobiol Int (2010) 1.07
Stress-related sleep disturbance and polysomnographic response to caffeine. Sleep Med (2006) 1.06
Insomnia pharmacotherapy. Neurotherapeutics (2012) 1.05
Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep (2006) 1.04
Sleep reactivity and insomnia: genetic and environmental influences. Sleep (2011) 1.03
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol (2013) 1.02
Pain sensitivity in sleepy pain-free normals. Sleep (2009) 1.02
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath (2007) 1.02
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med (2007) 1.01
Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol (2008) 1.01
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2011) 1.01
The venom composition of the parasitic wasp Chelonus inanitus resolved by combined expressed sequence tags analysis and proteomic approach. BMC Genomics (2010) 1.00
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry (2008) 0.99
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep (2011) 0.99
A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin (2006) 0.99
Pain sensitivity and recovery from mild chronic sleep loss. Sleep (2012) 0.99
Changes in depressive symptoms after continuous positive airway pressure treatment for obstructive sleep apnea. Sleep Breath (2003) 0.99
'Hypnotic' prescription patterns in a large managed-care population. Sleep Med (2004) 0.97
Cortical locations of maximal spindle activity: magnetoencephalography (MEG) study. J Sleep Res (2009) 0.97
Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. Neuropsychopharmacology (2002) 0.96
Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorder. Chronobiol Int (2012) 0.96
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol (2006) 0.96
Vulnerability to insomnia: the role of familial aggregation. Sleep Med (2007) 0.96
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep (2009) 0.96
Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep (2012) 0.95
Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl) (2011) 0.95
An epidemiologic study of sleep-disordered breathing symptoms among adolescents. Sleep (2006) 0.95
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol (2009) 0.93
Identification of bracovirus particle proteins and analysis of their transcript levels at the stage of virion formation. J Gen Virol (2010) 0.93